Background and purpose: SPG7 is one of the most common forms of autosomal recessive hereditary
Introduction
Hereditary spastic paraplegia (HSP) and hereditary ataxia (HA) are clinically and genetically heterogeneous disorders. HSP is characterized by progressive spastic paraparesis with varying degrees of bladder involvement and mild sensory dysfunction in the lower limbs [1] , while HA is characterized by progressive gait and limb ataxia, loss of coordination and disturbances of oculomotor control [2] . Classically, the disorders are divided into pure and complex forms, depending on the presence of additional neurological signs [3] . Both HSP and HA may be inherited in an autosomal dominant (AD), recessive (AR) or X-linked manner and more than 100 disease-causing genes have been identified [1, 2] . Phenotypically, HSP and HA are frequently overlapping, such as in Spastic paraplegia 7 (SPG7), caused by mutations in the SPG7 gene. SPG7 encodes paraplegin, a member of the AAA family of ATPases, located at the inner mitochondrial membrane. SPG7 was first described as a rare AR HSP [4] . During the last years, both dominant inheritance [5] [6] [7] , and a wider phenotypic spectrum have been described. SPG7 is frequently associated with cerebellar involvement [8, 9] , as well as optic neuropathy [6] , supranuclear palsy [10] , ptosis and progressive external ophthalmoplegia (PEO). PEO is associated with mitochondrial disorders, especially where mutations in nuclear genes lead to multiple deletions in mitochondrial DNA, which is consistent with the role paraplegin is found to play in mitochondrial DNA maintenance [11, 12] .
In 2008 the prevalence of AR HSP was estimated to 0.6/100 000 and the total prevalence of HSP to 7.4/100 000 in southeast Norway [13] . As expected from other populations, mutation in the SPG4 gene was reported as the most common cause of AD HSP, and mutations in the SPG11 gene as the most common cause of AR HSP in Norway [14] . At the time, the SPG7-gene was not included in the diagnostic work-up, and thus not identified. The first Norwegian family with mutations in SPG7 was described in 2008 [15] . Two additional families were reported in 2014 [11] .
Due to the genetic and clinical heterogeneity in HSP, the traditional targeted genetic testing represents a major diagnostic challenge. With the development of high-throughput sequencing (HTS), whole-exome sequencing (WES) has made it possible to look for disease-causing variants in all protein-coding genes, comprising about 1.5% of the entire genome. This genetic screening is of particular value in genetically heterogeneous monogenic diseases, although it introduces interpretation challenges. These new methods have led to identification of more SPG7 patients, making SPG7 a frequent cause of AR HSP in Norway, consistent with reports from other European populations [6, 16] . The aim of this study was to clinically and genetically characterize patients with SPG7 in Norway. We describe six Norwegian families with SPG7 and provide evidence of a novel founder mutation p.H701P which is hitherto only found in Norwegian patients. 
Material and methods

Patients
Genetic analyses
Families A-C were diagnosed by Sanger sequencing as previously described [11, 15] , whereas families D-F were diagnosed through WES. We performed targeted enrichment of the exome using the Agilent SureSelect Human All Exon kit v4. Sequencing was performed on an Illumina HiSeq2000 with 100 bp paired-end reads. Reads were aligned to the reference human genome (hg19) using Novoalign (V2.07.17) (http://www.novocraft.com/products/novoalign) and the Genome Analysis Toolkit (GATK, v2.4-9) [19, 20] . Variant calling was performed using GATK (v2.4-9). Variants were annotated by ANNOVAR (2012 May 25) [21] . Downstream filtering and analysis was done in Filtus (http://folk.uio.no/magnusv/filtus.html), using allele frequencies, conservation scores (GERP) and various in silico prediction tools [22] [23] [24] [25] option [26] .
Results
Clinical description
Clinical findings are reported in detail in Table 1 . The core findings were spasticity and hyperreflexia in the lower limbs (11/11), urge incontinence (11/11), ataxia (10/11), hyperreflexia in the upper limbs (9/11), ptosis (9/11) and progressive external ophthalmoplegia (PEO) (8/11). Cerebellar atrophy was present on MRI in all patients (Fig. 2 ). Patient FIII-1 had complicating features with epilepsy, possibly due to birth asphyxia, as well as cervical myelopathy due to disc herniation with medullar impression in C3/C4. These features were not present in the sibling FIII-2. Serum creatinine kinase (CK) levels were available in seven patients and all were within normal range. Nutritional status was in general reported as good, without evidence of wasting or dysphagia. The symptoms were progressive in all patients. In patient EIII-1, examinations with a ten-year interval showed an increase in SPRS from 7 to 29, and in SARA from 12 to 26.5. In a two-year interval, patient FIII-2 showed an SPRS increase of 16.5 to 21 and SARA increase of 9.5 to 13. IQ assessments were previously reported in three patients (AIV-2, BIII-2, BIII-4) [11] , with total IQ ranging from 78 to 79 and a more pronounced verbal than executive IQ impairment in all [27] . Only one of the patients was full-time employed at the time of examination and only one had an academic education. Psychiatric problems were reported in 5/6 families, with symptoms of depression and anxiety as the most frequent.
Genetic analyses
The variants identified in SPG7 are listed in Table 1 . In silico predictions and conservation scores of the missense variants were analysed in SIFT, PolyPhen2 and GERP and are listed in Table 3 .
Segregation analysis confirmed that the variants were in trans, except in family D where no additional family members were available for analysis. In the families who underwent WES, we did not identify additional variants in other genes related to HSP or HA which were considered pathogenic.
Haplotype analysis was performed using genotypes from seven SNPs surrounding the SPG7 gene.
In families A and F phasing was unique, assuming no recombination or mutation. In particular, both patients in family A were homozygous for all markers, thus determining the haplotype carrying p.H701P. Furthermore, family F gave haplotypes surrounding the p.A510V and p.K588T variants, respectively. In families B, D and E phasing was not unique, due to too few available family members.
However, in all three cases the genotypes matched the haplotypes identified in families A and F (Fig.   1 ). As each of these haplotypes contains several low frequency alleles, this is unlikely to occur by chance. Thus, we identified a shared haplotype co-segregating with the p.H701P mutation in all four families with this mutation, supporting that this is a founder mutation in the Norwegian population.
Discussion
By using both the traditional phenotype-guided sequencing of single candidate genes, and the HTS parallell sequencing approach, we have identified 13 SPG7 patients in the Norwegian population, making SPG7 the second most common recessive paraplegia in Norway. In our cohort of 28 probands with autosomal recessive HSP, 21% (6) are now diagnosed as SPG7, 25% (7) as SPG11 and 7% (2) as SPG5. Among these, only SPG11 has been available for Sanger sequencing in a diagnostic laboratory Norway, which probably biases our results. To the best of our knowledge, these are all the identified families with SPG7 in southeast and west Norway, covering about 4/5 of the Norwegian population.
SPG7 is traditionally classified as HSP. However, as ataxia is increasingly recognized as a major feature, SPG7 could also be classified as a spastic ataxia [28] . Interestingly, paraplegin is the binding partner of AFG3L2 on the inner mitochondrial membrane. Mutations in AFG3L2 causes the dominant ataxia SCA28 [29] , and this may explain the association between ataxia and spastic paraparesis in SPG7. A recently published study even showed that SPG7 is a common cause of undiagnosed ataxia presenting in mid-adult life [16] . SPG7 is a good example of a phenotype which is difficult to fit into the dichotomy of the traditional classification system. This is important to remember when chosing molecular work-up for patients.
There appears to be a core phenotype for SPG7 in the Norwegian population, which includes spastic paraparesis with ataxia, PEO, bladder disturbances and slight cognitive impairment. Thus, these symptoms and a possible AR inheritance pattern should raise the suspicion of SPG7. The only patient without clinical ataxia had cervical myopathy due to cervical disc herniation, which may have skewed the clinical picture towards spastic paraparesis; however MRI revealed mild cerebellar atrophy.
Signs of cognitive deficit, more pronounced verbal than executive, were present in the patients tested. In addition, psychiatric symptoms were observed in most families, and the clinical impression of mild anosognosia was noted in several patients. All these features are present in the clinical description of the Cerebellar Cognitive Affective Syndrome (CCAS), which is increasingly recognized in cerebellar disorders [30] . Bladder symptoms were reported as one of the patients' main problems and should be carefully addressed in the clinic, as it may have significant impact on the patients' quality of life. As bladder problems are seldom reported in hereditary ataxias, urge incontinence could be a diagnostic clue to differentiate SPG7 from other hereditary ataxias.
The families have no known common ancestors, though four share the same missense mutation c.2102A>C; p.H701P which has only been described in Norwegian patients. The variant co-segregates with disease in these families and is believed to be pathogenic. It was absent in 384 Norwegian control alleles, and the mutation changes a highly conserved histidine to proline in the catalytic Pfam metallopeptidase domain of paraplegin [11] , where most of the known pathogenic mutations in paraplegin occur [31] .The variant is not present in neither the esp6500, nor the 1000G database, and has only been reported four times in heterozygous state in the ExAC database (www.exac.broadinstitute.org), resulting in the low frequency of 3.4E-05.
Haplotype analysis revealed that all patients having the p.H701P variant also share a common haplotype covering 1.3 Mb region surrounding the variant (see Fig. 1 ), which indeed supports that this variant represents a founder mutation. This variant is involved in four of the six identified
Norwegian families with SPG7 and is thus a major cause of SPG7 in Norway.
The mutation c.1672A>T in family F causes a premature stop codon, p.K588X. It has been reported once before in a homozygous state in a man with late onset spastic paraparesis [8] and is believed to be disease causing. The variant c.1529C>T; p.A510V present in families D-F is the most common cause of SPG7 and has been shown to co-segregate with disease in several studies from different countries [32] . It was originally considered a polymorphism due to high carrier frequency [33], but both in silico analysis and functional studies in yeast suggest a pathogenic effect [34] and more recent studies conclude that this is a disease-causing mutation [7, 32] .
Conclusions
SPG7 causes at least 21% of the AR HSP cases in a large Norwegian cohort. Core phenotype includes PEO, bladder disturbances and spastic ataxia, the latter emphasizing the prominent role of ataxia in SPG7. Moreover, a variant p.H701P appears to be unique for Norwegian patients and resides on a founder haplotype. 
